 Show A nurse in an acute mental health facility is reviewing the medication records for a group of clients. The nurse should expect a prescription for memantine for a client who has which of the following diagnoses? Alzheimer's disease Rationale: The nurse should expect a prescription for memantine for a client who has moderate to severe Alzheimer's disease. Memantine, an NMDA receptor agonist, is shown to slow the progression of manifestations and to improve cognitive function. A nurse is collecting data from a client who takes an MAOI for the treatment of depression. Which of the following findings is the priority for the nurse to report to the provider? Elevated blood pressure Rationale: The nurse should identify that the greatest risk to the client is an elevated blood pressure, which increases his risk for a hypertensive crisis that can result from taking an MAOI. The nurse should apply the safety and risk reduction priority-setting framework when collecting data from this client. This framework assigns priority to the factor or situation posing the greatest safety risk to the client. When there are several risks to client safety, the one posing the greatest threat is the highest priority. The nurse should use Maslow's hierarchy of needs, the ABC priority-setting framework, or nursing knowledge to identify which risk poses the greatest threat to the client. A nurse is reviewing the medications of a client who has bipolar disorder and a new prescription for lithium. The nurse should identify that it is safe to administer which of the following medications while the client is taking lithium? Valproic acid Rationale: Valproic acid and lithium are both indicated for the treatment of bipolar disorder. It is safe for the nurse to administer both of these medications to the client. A nurse is collecting data from a client who has cocaine intoxication. Which of the following findings should the nurse expect? Increased maternal alertness Rationale: The nurse should expect a client who has cocaine intoxication to have increased mental alertness due to its stimulant properties. A nurse is caring for a client who has schizophrenia. The nurse notices that the client is pacing up and down the hall very rapidly and muttering in an angry manner. Which of the following actions should the nurse take first? Approach the client in a non threatening manner Rationale: Continuing Education ActivityBipolar affective disorder is a chronic and complex disorder of mood that is characterized by a combination of manic (bipolar mania), hypomanic and depressive (bipolar depression) episodes, with substantial subsyndromal symptoms that commonly present between major mood episodes. It is one of the top causes of worldwide disability. Bipolar 1 disorder has been frequently associated with serious medical and psychiatric comorbidity, early mortality, high levels of functional disability, and compromised quality of life. The necessary feature of bipolar 1 disorder involves the occurrence of at least one lifetime manic episode, although depressive episodes are common. Bipolar 2 disorder needs the occurrence of at least one hypomanic episode and one major depressive episode. This activity reviews the etiology, pathophysiology, evaluation, and management of bipolar affective disorder and highlights the role of the interprofessional team in managing and improving care for patients with this condition. This activity also addresses the prognosis of bipolar affective disorder. Objectives:
Access free multiple choice questions on this topic. Introduction"Mood" is defined as a ubiquitous and sustained feeling or emotion that dominates a person’s behavior and affects his perception. Mood disorders also known as affective disorders include unipolar and bipolar disorders. Hippocrates was the first to distinguish between different dispositions or humors--melancholic, choleric, phlegmatic, sanguine--but it was Jules Farley in 1854, who first described folie circulaire or the alternating cycle of euphoria and melancholia. In 1899, Emil Kraepelin then further elaborated upon this burgeoning nosological distinction as he distinguished the psychosis observed in manic-depressive disorders from that of dementia praecox (i.e. schizophrenia). Manic-depressive disorder--more contemporarily identified as bipolar disorder (BD)--is a chronic and complex disorder of mood that is characterized by a combination of manic, hypomanic, and depressive episodes, with subsyndromal symptoms extant in between the mood episodes.[1] It is one of the leading causes of worldwide disability and morbidity.[2] BD has been frequently associated with serious medical and psychiatric comorbidity, early mortality, high levels of functional disability, and compromised quality of life.[3] BD can be further subdivided into bipolar disorder I (BD I) and bipolar disorder II (BD II). The quintessential feature of BD I is the manifestation of at least one manic episode--although depressive episodes are common, only one manic episode in a lifetime is enough to label one with BD I. To be diagnosed with BD II, one must experience at least one hypomanic episode, without any history of any manic episodes. Both of these aforementioned manifestations must precipitate in the absence of any substance, iatrogenic agent, or organicity as such extant associations would be indicative of the diagnoses of 'substance/medication-induced bipolar and related disorder' and 'bipolar and related disorder due to another medical condition', respectively. Additionally, a less elucidated derivative of the bipolar spectrum is 'cyclothymic disorder' which is more analogous to a personality disorder in its chronicity and pervasiveness. EtiologyBipolar affective disorder can be caused by a variety of factors.[4] Some of those are listed below: Biological Factors
Psychosocial Factors
EpidemiologyIn the general population, the lifetime prevalence of BD is around 1% for BD I.[8][9] A large cross-sectional survey of 11 countries noted that the overall lifetime prevalence of bipolar spectrum disorders was 2-3%, with a prevalence of 0.4% for BD II.[10] Because of the ambiguity of its phenomenology, epidemiologic data on cyclothymia is equivocal, suggestive of a range of 0.5 to 6.3%. Most studies suggest that BD I has an equal prevalence in both men and women, while others have recognized a higher prevalence of manic episodes--and thus bipolar type 1--in males and higher rates of bipolar type 2 in females.[10][11] Overall, the evidence is suggestive of an equal distribution between genders and ethnicity. The mean age of onset of bipolar disorder is in early adulthood--18 to 20 years of age--although some findings are indicative of a later onset (>25 years of age).[9] A bimodal distribution has also been suggested, as noted by a large population-based cohort study, which found peaks in the age of onset at 15 to 24 years and at 45 to 54 years.[12][13] Of note, the precise distinction of the age of onset of BD is difficult to decipher as it can precipitate with subsyndromal manifestations or even be misattributed to another affective disorder. Patients with mood disorders are at an increased risk of death by suicide. The incidence of death by suicide among patients with a diagnosis of bipolar affective disorder has been reported to be as high as 20 times more than the general population-- most notably when bipolar disorder is untreated.[14][15][16][17] About one in three to one in two patients with bipolar disorder attempt suicide at least once in the course of their lifetime, and approximately 15–20% of attempts are successful.[18] PathophysiologyBipolar affective disorder is considered one of the most heritable psychiatric disorders; however, a multifactorial model, in which genes and the environment, in parallel with psychosocial stressors, dynamically interact to precipitate this phenomenon, is presently thought to be responsible.[19] Many alleles of small effect, which somewhat overlap with schizophrenia (e.g., CACNA1C, TENM4, and NCAN) and are described in genome-wide association studies, add to the polygenic risk of bipolar disorder.[19] Neurotrophic molecules, such as brain-derived neurotrophic factor (BDNF), have an important role in signaling pathways of dendritic sprouting and neural plasticity.[20] Dendritic spine loss has been observed in the post-mortem brain tissue of patients with bipolar affective disorder.[21] Other pathways that can affect neuronal interconnectivity are also being studied, which include dysfunction of mitochondria and endoplasmic reticulum stress, neuroinflammation, apoptosis, oxidation, and epigenetic changes, particularly histone and DNA methylation.[22] History and PhysicalThe presentations of mania and depression will now be elucidated, however, patients can present in a mixed state which includes features from both 'poles' of BD. General Appearance A patient with mania is often hyperkinetic, unpredictable, and erratic. They often are garishly dressed, display negligence of social propriety--demonstrable via excessive friendliness, boundary violations, agitation, or other improprieties--and appear to be unnaturally "happy" or euphoric, however, irritability is also observed, dispositionally. Mood and Affect As previously stated, the mood is often elevated or euphoric, in mania. Affect is often heightened, intense, and extremely lability. Implicit with the affective lability of mania are hyperactivity and severe mobility. When presenting in a depressive state, the patient will report a sad or elegiac mood, while expressing a congruent affect (often tearful). Speech A manic patient will demonstrate pressured speech, which implies a rapid and continuous production of speech that is difficult to interrupt. Reciprocally, speech is slow and soft, in depression. Perception Mood congruent delusions may be present in either the depressed or manic phase (e.g. delusions of guilt during depressed phases or grandiose delusions of power and wealth during manic phases) A manic patient can also have mood-incongruent delusions. Thought Process and Content Patients with mania demonstrate easy distractibility, lack of concentration, illogical condensations, delusions of grandiosity, and flight of ideas. A depressed patient usually has negative thoughts and negative ruminations. Sensorium and Cognition Usually oriented to person, place, and time. Depressed patients may have some impairment in cognition and memory. Manic patients may have a grossly intact memory. Sometimes orientation is impaired and is called manic delirium. Impulse Control Extremely depressed patients demonstrate avolition and abulia--lack of willpower. It has been postulated that suicidal ideation originates during the depressive phases and is made manifest upon the transition to baseline or a subsequent manic state. Manic patients are threatening and assaultive. Judgment and Insight Impaired judgment is the distinctive feature of mania along with limited insight. Depressed patients often overemphasize their symptoms. Reliability Manic patients are usually unreliable in the information they provide. Depressed patients overemphasize negative symptoms and treatment failure. EvaluationThe correct diagnosis of bipolar affective disorder is facilitated, to a large degree, by a general clinical psychiatric assessment with the patient and their relatives, to recognize the longitudinal course of the disorder. Organicity, along with substance and iatrogenic causes, must first be ruled out, entailing a comprehensive medical examination (e.g. urine drug screen, serum alcohol levels, urinalysis, thyroid panel, medication profile, etc). Most laboratory results in BD are within normal limits. If the patient has already been diagnosed with bipolar affective disorder and has been on mood stabilizers for treatment, consider serum lithium, serum valproic acid levels, serum lamotrigine levels, or serum carbamazepine levels to determine therapeutic levels in order to titrate medication. According to DSM-V Mania, which is a feature of BD I, is diagnosable when:
Hypomania, which can be a feature of BD I, BD II, or cyclothymia, is diagnosable when:
Major depressive episodes are present in BD I, BD II, but not required for diagnosis. Five or more symptoms listed below present for more than two weeks which cause impairment in social and occupational functioning:
The symptoms are not secondary to medication, illicit drugs, or other medical conditions. The patient can also present with 'mixed features' signaling episodes of mania, depression, or hypomania accompanied by features of the opposite polarity. Manic or hypomanic episodes are signified with the distinction 'mixed features' when either full criteria for mania or hypomania is met along with at least 3 of the following symptoms: depressed mood, psychomotor retardation, asthenia, guilt, suicidal ideation, or anhedonia. Major depressive episodes are distinguished as mixed when the full criteria for major depression are met along with at least 3 of the following symptoms: elevated mood, grandiosity, verbose, flight of ideas, hyperkinesis, impulsivity, or insomnia. When diagnosing bipolar disorder, it must be specified if the disorder is:
Treatment / ManagementThe primary step in the management of bipolar affective disorder is to confirm the diagnosis of mania or hypomania and define the patient’s mood state as the treatment approach differs significantly for hypomania, mania, depression, and euthymia. Various factors can affect pharmacological and psychological approaches; these comprise medical and psychiatric comorbidities, past or current treatments, treatment response or adverse effects in patients and relatives, and the patient’s inclination to be treated. In acute management, the primary goals are to ensure the safety of patients and nearby people, achieve clinical and functional stabilization with the least possible adverse effects. Additionally, engagement in treatment and development of a therapeutic alliance is important in any chronic disorder that requires long-term adherence, and this collaboration is especially true during the first episode.[23] Mood stabilizers and antipsychotics are the foundation of acute management of bipolar mania and depression.[24] Mood stabilizers are the main pharmacological agents for the treatment of bipolar affective disorder, particularly in the maintenance phase of mania. Lithium is the gold standard for the treatment of bipolar disorder as long-term use has demonstrated a reduction in suicide risk. 50%-70% of patients treated with lithium show a reduction in mania. However, lithium has a narrow therapeutic index, and serum lithium levels should be monitored. Carbamazepine and valproic acid are anticonvulsants that have a mood-stabilizing effect and are also utilized in many cases for acute manic episodes. Second generation or atypical antipsychotics like olanzapine, quetiapine, risperidone, ziprasidone are indicated as monotherapy or in combination with a mood stabilizer. Combination therapy using a mood stabilizer and an antipsychotic has shown a greater response than treatment with either single agent.[25][26] Of note, lurasidone is considered highly effective for depressive symptoms in bipolar affective disorder.[27] The FDA has approved 4 psychotropics in the setting of acute bipolar depression: lurasidone, cariprazine, quetiapine, and the olanzapine-fluoxetine combination. Notably, evidence for the use of antidepressants to treat depression is not well understood, and these drugs should never be used as monotherapy in BD.[28] It has also been postulated that antidepressants can trigger a manic episode in patients with bipolar affective disorder, which is defined as a 'treatment emergent switch' or TEA. Electroconvulsive therapy is extremely effective for treatment-resistant acute mood episodes like refractory depression or acute life-threatening mania, predominantly in patients with psychotic or catatonic features, and it is the best treatment for mania in a pregnant female.[29] In long-term management, the main objectives are to prevent relapse of episodes and ensure functionality while optimizing treatment. Pharmacotherapy, usually consisting of a mood stabilizer alone or in combination with antipsychotic or antidepressant plus customized psychosocial interventions in euthymia, can reduce the chance of relapse, enhance treatment adherence, and decrease the number and duration of hospital admissions.[30][31] Psychoeducation has been shown to have significant prophylactic effects in individuals with bipolar disorder.[32][33] Other valuable treatments for patients include cognitive behavioral therapy, interpersonal and social rhythm therapy, and family-focused therapy.[34][35][36] Functional remediation has also shown efficacy in enhancing functioning ability in patients with bipolar 1 and bipolar 2 disorder with psychosocial functional deficits.[37][38] Bipolar depression often persists longer, and it is very challenging to treat, needing a different approach from that used in unipolar depression. The broad consensus is that quetiapine, olanzapine, lamotrigine, lurasidone, and antidepressants have some efficacy but show varying tolerability. Differential Diagnosis
Toxicity and Side Effect ManagementMedical comorbidities are quite prevalent in patients with bipolar disorder because of the adverse effects of treatment with mood stabilizers, anticonvulsants, antipsychotics, genetic vulnerability, and lifestyle factors (poor diet, lack of exercise, alcohol use, smoking). Keeping in mind the burden of these comorbidities and adverse effects of pharmacotherapy, regular monitoring of weight, glycemia, dyslipidemia, blood pressure, and liver function is necessary for patients with bipolar affective disorder.[39] Blood concentrations of lithium and valproate, when taken by the patient, should be regularly monitored to ensure they are within the therapeutic range. In addition, renal and thyroid function testing is necessary because treatment with lithium is known to be associated with tubulointerstitial nephropathy, hypothyroidism, and nephrogenic diabetes insipidus.[39] For patients receiving valproate, the hepatic function should be monitored, and, in women, cases of polycystic ovary disease are known with valproate therapy. PrognosisBipolar 1 disorder usually has a poor prognosis. 50% of patients experience a second episode within two years of the first episode. Poor prognosis is associated with:
Lithium prophylaxis improves prognosis in about 50% of patients. About 45% of patients have a chronic disorder. The mean number of episodes of mania is 9, and the range is 2-30. More episodes indicate a poorer prognosis. As discussed above, patients with bipolar affective disorder are at higher risk for suicidal ideation and attempts, which lead to a poorer prognosis. ComplicationsThe bipolar affective disorder has a progressive course and has implications on the patient’s cognitive and functional domains, in addition to affecting their physical health. Although patients with bipolar disorder may have normal or even higher cognition before diagnosis in many cognitive and neuroimaging studies, bipolar disorder has been related to significant neurocognitive deficits through all mood states, including periods of remission.[40][41][42] In addition to cognition and functioning, physical health is also affected profoundly in patients with bipolar disorder[43] Incidence of obesity, cardiovascular disorders, and diabetes is higher and arise earlier in the life course compared with the general population.[44] There are reports of increased mortality as well, with findings of one study which followed patients over a 30-year period showing that circulatory disorders and suicide are the main causes of death.[45] Deterrence and Patient EducationIt is important to educate patients and families on the importance of medication compliance, signs of hypomania, and mania. One of the greatest challenges includes ongoing engagement with treatment as most patients experience multiple manic, hypomanic, or depressive episodes in their life, and this is often secondary to medication non-compliance. Patients are asked to engage with both therapists and psychopharmacologists regularly and even support groups. Often patients may relapse even when they are adherent to medications. Support and ongoing psychoeducation of both patients and families are crucial in ongoing treatment. Enhancing Healthcare Team OutcomesBipolar affective disorder is a serious mental disorder that results in impairments in the functionality of daily life, leading to increased costs for both patients and society. It is a multifaceted disease, and a comprehensive biological, social, and psychological approach should be employed in its management. The diagnosis of bipolar affective disorder frequently poses a diagnostic challenge. These patients may exhibit a variety of signs and symptoms such as depression, hypomania, mania, irritability, insomnia resulting in psychological distress over a long period of time. It is not always easy to obtain the exact timeline and chronology of symptoms, which frequently results in misdiagnosis. While the mental status exam of the patient may point towards the diagnosis of bipolar affective disorder, it is usually difficult to obtain a proper history of the patient's symptoms in one clinical visit. It is important to engage the patient in an empathic way and develop a therapeutic alliance to facilitate better treatment results. While a psychiatrist or nurse practitioner is almost always involved in the care of patients with bipolar affective disorder, it is important to obtain input about the patient's behavior and symptoms from the interdisciplinary psychologists, activity therapists, nurses, nurse practitioners, physician assistants, pharmacists, behavioral health associates, and social workers especially in the inpatient unit and emergency services while taking care of the patient in these settings. Nurses are vital members of the interprofessional group as they monitor the patient's behavior, medication compliance, vital signs, and assist with psychoeducation of the patient and family. Psychopharmacologists are specialized in the field of psychotropic medications and called upon for complex medication management and education. To improve outcomes, an interdisciplinary approach is a mainstay in the treatment of patients with bipolar disorder. An interprofessional team that provides a holistic and integrated approach to patient care can help achieve the best possible outcomes. Once the patient is discharged to home, shelter, or supportive housing, consultation should be made with a social worker and community nurses who can monitor the patient and make referrals as needed. Review QuestionsReferences1.Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016 Apr 09;387(10027):1561-1572. [PubMed: 26388529] 2.Whiteford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos T. The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010. PLoS One. 2015;10(2):e0116820. [PMC free article: PMC4320057] [PubMed: 25658103] Blanco C, Compton WM, Saha TD, Goldstein BI, Ruan WJ, Huang B, Grant BF. Epidemiology of DSM-5 bipolar I disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions - III. J Psychiatr Res. 2017 Jan;84:310-317. [PMC free article: PMC7416534] [PubMed: 27814503] 4.Miklowitz DJ, Johnson SL. The psychopathology and treatment of bipolar disorder. Annu Rev Clin Psychol. 2006;2:199-235. [PMC free article: PMC2813703] [PubMed: 17716069] 5.McGuffin P, Rijsdijk F, Andrew M, Sham P, Katz R, Cardno A. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry. 2003 May;60(5):497-502. [PubMed: 12742871] 6.Keener MT, Phillips ML. Neuroimaging in bipolar disorder: a critical review of current findings. Curr Psychiatry Rep. 2007 Dec;9(6):512-20. [PMC free article: PMC2686113] [PubMed: 18221633] 7.Manji HK, Quiroz JA, Payne JL, Singh J, Lopes BP, Viegas JS, Zarate CA. The underlying neurobiology of bipolar disorder. World Psychiatry. 2003 Oct;2(3):136-46. [PMC free article: PMC1525098] [PubMed: 16946919] 8.Bebbington P, Ramana R. The epidemiology of bipolar affective disorder. Soc Psychiatry Psychiatr Epidemiol. 1995 Nov;30(6):279-92. [PubMed: 8560330] 9.Pini S, de Queiroz V, Pagnin D, Pezawas L, Angst J, Cassano GB, Wittchen HU. Prevalence and burden of bipolar disorders in European countries. Eur Neuropsychopharmacol. 2005 Aug;15(4):425-34. [PubMed: 15935623] 10.Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, Viana MC, Andrade LH, Hu C, Karam EG, Ladea M, Medina-Mora ME, Ono Y, Posada-Villa J, Sagar R, Wells JE, Zarkov Z. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011 Mar;68(3):241-51. [PMC free article: PMC3486639] [PubMed: 21383262] 11.Tsuchiya KJ, Byrne M, Mortensen PB. Risk factors in relation to an emergence of bipolar disorder: a systematic review. Bipolar Disord. 2003 Aug;5(4):231-42. [PubMed: 12895201] 12.Kessing LV. Diagnostic subtypes of bipolar disorder in older versus younger adults. Bipolar Disord. 2006 Feb;8(1):56-64. [PubMed: 16411981] 13.Kroon JS, Wohlfarth TD, Dieleman J, Sutterland AL, Storosum JG, Denys D, de Haan L, Sturkenboom MC. Incidence rates and risk factors of bipolar disorder in the general population: a population-based cohort study. Bipolar Disord. 2013 May;15(3):306-13. [PubMed: 23531096] 14.Kapczinski NS, Narvaez JC, Magalhães PV, Bücker J, Peuker AC, Loredo AC, Troiano F, Czepielewski L, Rosa A, Fries GR, Gama CS. Cognition and functioning in bipolar depression. Braz J Psychiatry. 2016 Jul-Sep;38(3):201-6. [PMC free article: PMC7194267] [PubMed: 26870909] 15.Tondo L, Isacsson G, Baldessarini R. Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs. 2003;17(7):491-511. [PubMed: 12751919] 16.Pompili M, Gonda X, Serafini G, Innamorati M, Sher L, Amore M, Rihmer Z, Girardi P. Epidemiology of suicide in bipolar disorders: a systematic review of the literature. Bipolar Disord. 2013 Aug;15(5):457-90. [PubMed: 23755739] 17.Gibbons RD, Hur K, Brown CH, Mann JJ. Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder. Arch Gen Psychiatry. 2009 Dec;66(12):1354-60. [PMC free article: PMC3926811] [PubMed: 19996040] 18.Schaffer A, Isometsä ET, Tondo L, H Moreno D, Turecki G, Reis C, Cassidy F, Sinyor M, Azorin JM, Kessing LV, Ha K, Goldstein T, Weizman A, Beautrais A, Chou YH, Diazgranados N, Levitt AJ, Zarate CA, Rihmer Z, Yatham LN. International Society for Bipolar Disorders Task Force on Suicide: meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disord. 2015 Feb;17(1):1-16. [PMC free article: PMC6296224] [PubMed: 25329791] 19.McIntyre RS, Konarski JZ, Soczynska JK, Wilkins K, Panjwani G, Bouffard B, Bottas A, Kennedy SH. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv. 2006 Aug;57(8):1140-4. [PubMed: 16870965] 20.Grande I, Fries GR, Kunz M, Kapczinski F. The role of BDNF as a mediator of neuroplasticity in bipolar disorder. Psychiatry Investig. 2010 Dec;7(4):243-50. [PMC free article: PMC3022310] [PubMed: 21253407] 21.Konopaske GT, Lange N, Coyle JT, Benes FM. Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder. JAMA Psychiatry. 2014 Dec 01;71(12):1323-31. [PMC free article: PMC5510541] [PubMed: 25271938] 22.Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, Yücel M, Gama CS, Dodd S, Dean B, Magalhães PV, Amminger P, McGorry P, Malhi GS. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011 Jan;35(3):804-17. [PubMed: 20934453] 23.Berk L, Hallam KT, Colom F, Vieta E, Hasty M, Macneil C, Berk M. Enhancing medication adherence in patients with bipolar disorder. Hum Psychopharmacol. 2010 Jan;25(1):1-16. [PubMed: 20041478] 24.Grande I, Vieta E. Pharmacotherapy of acute mania: monotherapy or combination therapy with mood stabilizers and antipsychotics? CNS Drugs. 2015 Mar;29(3):221-7. [PubMed: 25711483] 25.Malhi GS, Tanious M, Berk M. Mania: diagnosis and treatment recommendations. Curr Psychiatry Rep. 2012 Dec;14(6):676-86. [PubMed: 22986995] 26.Grande I, Hidalgo-Mazzei D, Nieto E, Mur M, Sàez C, Forcada I, Vieta E. Asenapine prescribing patterns in the treatment of manic in- and outpatients: Results from the MANACOR study. Eur Psychiatry. 2015 Jun;30(4):528-34. [PubMed: 25682181] 27.Fornaro M, De Berardis D, Perna G, Solmi M, Veronese N, Orsolini L, Buonaguro EF, Iasevoli F, Köhler CA, Carvalho AF, de Bartolomeis A. Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews. Biomed Res Int. 2017;2017:3084859. [PMC free article: PMC5440797] [PubMed: 28573138] 28.Vieta E. Antidepressants in bipolar I disorder: never as monotherapy. Am J Psychiatry. 2014 Oct;171(10):1023-6. [PubMed: 25272338] 29.Schoeyen HK, Kessler U, Andreassen OA, Auestad BH, Bergsholm P, Malt UF, Morken G, Oedegaard KJ, Vaaler A. Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment. Am J Psychiatry. 2015 Jan;172(1):41-51. [PubMed: 25219389] 30.Vieta E, Langosch JM, Figueira ML, Souery D, Blasco-Colmenares E, Medina E, Moreno-Manzanaro M, Gonzalez MA, Bellivier F. Clinical management and burden of bipolar disorder: results from a multinational longitudinal study (WAVE-bd). Int J Neuropsychopharmacol. 2013 Sep;16(8):1719-32. [PubMed: 23663490] 31.Colom F, Vieta E, Martínez A, Jorquera A, Gastó C. What is the role of psychotherapy in the treatment of bipolar disorder? Psychother Psychosom. 1998;67(1):3-9. [PubMed: 9491434] 32.Colom F, Vieta E, Martinez-Aran A, Reinares M, Goikolea JM, Benabarre A, Torrent C, Comes M, Corbella B, Parramon G, Corominas J. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry. 2003 Apr;60(4):402-7. [PubMed: 12695318] 33.Colom F, Vieta E, Sánchez-Moreno J, Palomino-Otiniano R, Reinares M, Goikolea JM, Benabarre A, Martínez-Arán A. Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical trial. Br J Psychiatry. 2009 Mar;194(3):260-5. [PubMed: 19252157] 34.Scott J, Paykel E, Morriss R, Bentall R, Kinderman P, Johnson T, Abbott R, Hayhurst H. Cognitive-behavioural therapy for bipolar disorder. Br J Psychiatry. 2006 May;188:488-9. [PubMed: 16648539] 35.Frank E, Kupfer DJ, Wagner EF, McEachran AB, Cornes C. Efficacy of interpersonal psychotherapy as a maintenance treatment of recurrent depression. Contributing factors. Arch Gen Psychiatry. 1991 Dec;48(12):1053-9. [PubMed: 1845438] 36.Jensen AL, Iversen L, Høier R, Kristensen F, Henriksen P. Evaluation of an immunoradiometric assay for thyrotropin in serum and plasma samples of dogs with primary hypothyroidism. J Comp Pathol. 1996 Apr;114(3):339-46. [PubMed: 8762591] 37.Torrent C, Bonnin Cdel M, Martínez-Arán A, Valle J, Amann BL, González-Pinto A, Crespo JM, Ibáñez Á, Garcia-Portilla MP, Tabarés-Seisdedos R, Arango C, Colom F, Solé B, Pacchiarotti I, Rosa AR, Ayuso-Mateos JL, Anaya C, Fernández P, Landín-Romero R, Alonso-Lana S, Ortiz-Gil J, Segura B, Barbeito S, Vega P, Fernández M, Ugarte A, Subirà M, Cerrillo E, Custal N, Menchón JM, Saiz-Ruiz J, Rodao JM, Isella S, Alegría A, Al-Halabi S, Bobes J, Galván G, Saiz PA, Balanzá-Martínez V, Selva G, Fuentes-Durá I, Correa P, Mayoral M, Chiclana G, Merchan-Naranjo J, Rapado-Castro M, Salamero M, Vieta E. Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. Am J Psychiatry. 2013 Aug;170(8):852-9. [PubMed: 23511717] 38.Solé B, Bonnin CM, Mayoral M, Amann BL, Torres I, González-Pinto A, Jimenez E, Crespo JM, Colom F, Tabarés-Seisdedos R, Reinares M, Ayuso-Mateos JL, Soria S, Garcia-Portilla MP, Ibañez Á, Vieta E, Martinez-Aran A, Torrent C., CIBERSAM Functional Remediation Group. Functional remediation for patients with bipolar II disorder: improvement of functioning and subsyndromal symptoms. Eur Neuropsychopharmacol. 2015 Feb;25(2):257-64. [PubMed: 24906790] 39.Ng F, Mammen OK, Wilting I, Sachs GS, Ferrier IN, Cassidy F, Beaulieu S, Yatham LN, Berk M., International Society for Bipolar Disorders. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord. 2009 Sep;11(6):559-95. [PubMed: 19689501] 40.Tiihonen J, Haukka J, Henriksson M, Cannon M, Kieseppä T, Laaksonen I, Sinivuo J, Lönnqvist J. Premorbid intellectual functioning in bipolar disorder and schizophrenia: results from a cohort study of male conscripts. Am J Psychiatry. 2005 Oct;162(10):1904-10. [PubMed: 16199837] 41.Pomarol-Clotet E, Alonso-Lana S, Moro N, Sarró S, Bonnin MC, Goikolea JM, Fernández-Corcuera P, Amann BL, Romaguera A, Vieta E, Blanch J, McKenna PJ, Salvador R. Brain functional changes across the different phases of bipolar disorder. Br J Psychiatry. 2015 Feb;206(2):136-44. [PubMed: 25497296] 42.Martínez-Arán A, Vieta E, Reinares M, Colom F, Torrent C, Sánchez-Moreno J, Benabarre A, Goikolea JM, Comes M, Salamero M. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry. 2004 Feb;161(2):262-70. [PubMed: 14754775] 43.Kilbourne AM, Cornelius JR, Han X, Pincus HA, Shad M, Salloum I, Conigliaro J, Haas GL. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord. 2004 Oct;6(5):368-73. [PubMed: 15383128] 44.Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, Miller DD, Haynes WG. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann Clin Psychiatry. 2008 Jul-Sep;20(3):131-7. [PMC free article: PMC2776768] [PubMed: 18633739] 45.Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord. 2002 Apr;68(2-3):167-81. [PubMed: 12063145] |
A nurse is collecting data from a client who has bipolar disorder and is in the manic phase
zusammenhängende Posts
Urheberrechte © © 2024 defrojeostern Inc.
